Skip to main
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc. has demonstrated significant growth in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units in the latest report, indicating strong demand for its myoelectric orthotic devices. The recent positive ruling from CMS to include the MyoPro in Medicare Part B benefits presents a substantial expansion opportunity in the Medicare market, potentially enhancing revenue streams. Additionally, with orthotics and prosthetics (O&P) providers accounting for approximately 22% of revenue expected in 2024, Myomo is strategically positioning itself to capitalize on the growing Medicare market and redirect its growth efforts effectively.

Bears say

Myomo Inc has significantly lowered its 2025 revenue guidance from $50–53 million to $40–42 million, indicating potential challenges in its financial performance. Additionally, the company's marketing efforts and quality of pipeline additions have been disappointing, negatively impacting lead quality and conversion rates. The authorized insurance backlog has decreased from 272 in Q4 to 208, suggesting a decline in demand for its myoelectric orthosis products and contributing to a negative outlook for the stock.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.